SK Biopharmaceuticals builds massive AI dataset to speed up drug discovery
SK Biopharmaceuticals, a Korean firm focused on developing original prescription drugs, has built a massive artificial intelligence (AI) dataset of more than 7 million chemical entries to streamline candidate screening for new therapies. The project is part of the Ministry of Science and ICT’s program to develop AI foundation models for specific fields. A foundation model is a large AI model…
Korean pharmaceutical company SK Biopharmaceuticals has constructed an extensive artificial intelligence (AI) dataset comprising over 7 million chemical entries to expedite the process of identifying potential treatments. This initiative is a component of the Ministry of Science and ICT’s endeavor to develop AI foundation models tailored to specific domains.
Foundation models are sophisticated AI systems trained on extensive data repositories that can be repurposed for various applications. SK Biopharmaceuticals collaborates within a health and medical consortium led by medical AI company Lunit, alongside Trillion Labs, Kakao Healthcare, and numerous other entities, including universities and hospitals.
The consortium initially created a foundational model specifically geared towards medical science, subsequently tailoring specialized versions for three key areas: pharmaceutical development, encompassing chemical compounds and proteins; omics, which refers to the comprehensive examination of genes and other biological molecules; and clinical trials.
To create the dataset for drug discovery, SK Biopharmaceuticals curated information necessary for laboratory operations. This dataset encompasses 66 facets of drug development, including predictive capabilities.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
